LP
INMB icon

LMR Partners’s INmune Bio INMB Stock Holding History

LMR Partners’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-41,600
Closed -$96.1K – 1543
2025
Q2 		$96.1K Buy
+41,600
New +$305K ﹤0.01% 1177

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LMR Partners's INMB Position: Q1 2026 in Review

LMR Partners held its INmune Bio (INMB) position steady in Q1 2026 at 16,600 shares worth $18.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1350.

LMR Partners first reported a position in INMB in Q3 2025 and has held it in 3 quarters since. The position peaked at $34.4K in Q3 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • LMR Partners held 16,600 shares of INmune Bio worth $18.8K as of Q1 2026.
  • LMR Partners left its INmune Bio share count unchanged in Q1 2026.
  • INmune Bio made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1350 holding.
  • LMR Partners first reported a position in INmune Bio in Q3 2025 and has held it in 3 quarters since.
  • LMR Partners's INmune Bio position peaked at $34.4K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.